By defining a very small specific interaction region of DRAIC and its target and finding that this same region is critical for inhibiting NF-κB and key cancer pathways, we strongly suggest that NF-κB inhibition is the key pathway by which DRAIC exerts its anticancer function. Here, NFKB1 is linked to cancer.